NVNO enVVeno Medical Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1661053 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY29.2%
TTM EPS YoY67.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-67.1%
ROA-60.0%
ROIC (approx.)-61.4%
Asset turnover—
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio7.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.88M | $2.08M | $2.11M | $1.95M | $2.58M | $2.89M | $2.56M | $3.51M |
| SG&A expense | $1.66M | $1.72M | $1.95M | $2.06M | $2.30M | $4.16M | $2.40M | $3.19M |
| Operating income | -$4.53M | -$3.80M | -$4.06M | -$4.01M | -$4.88M | -$7.05M | -$4.95M | -$6.70M |
| Net income | -$4.37M | -$3.60M | -$3.85M | -$3.74M | -$4.54M | -$6.69M | -$4.50M | -$6.23M |
| EBITDA | — | — | -$4.03M | -$3.98M | -$4.85M | -$7.01M | -$4.91M | -$6.66M |
| EPS (basic) | -6.29 | -5.37 | -5.89 | — | -7.89 | -11.52 | -7.75 | — |
| EPS (diluted) | -6.29 | -5.37 | -5.89 | — | -7.89 | -11.52 | -7.75 | — |
| Weighted avg. shares (diluted) | 694,000 | 671,000 | 654,000 | — | 575,000 | 581,000 | 581,000 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.58M | $2.84M | $2.60M | $3.06M | $1.54M | $2.04M | $2.94M | $1.75M |
| Short-term investments | $15.89M | $18.64M | $22.33M | $25.15M | $29.41M | $33.10M | $36.00M | $41.40M |
| Current assets | $19.02M | $22.08M | $25.49M | $28.83M | $31.50M | $35.60M | $39.48M | $43.73M |
| PP&E, net | $62,000 | $78,000 | $16,000 | $51,000 | $82,000 | $113,000 | $142,000 | $182,000 |
| Total assets | $19.49M | $22.66M | $26.10M | $29.56M | $32.35M | $36.58M | $40.58M | $44.95M |
| Current liabilities | $2.59M | $1.89M | $2.14M | $2.12M | $2.40M | $3.02M | $1.66M | $2.10M |
| Total liabilities | $2.59M | $1.99M | $2.35M | $2.43M | $2.90M | $3.52M | $2.27M | $2.79M |
| Shareholders' equity | $16.90M | $20.67M | $23.75M | $27.13M | $29.45M | $33.06M | $38.31M | $42.16M |
| Shares outstanding | 695,000 | 673,000 | 656,000 | 656,000 | 20.22M | 19.25M | 17.54M | 501,000 |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.18M | -$3.55M | -$3.24M | -$3.44M | -$4.39M | -$3.71M | -$4.02M | -$5.11M |
| Capital expenditure | — | — | — | $0 | $0 | — | — | $4,000 |
| Free cash flow | — | — | — | -$3.44M | -$4.39M | — | — | -$5.11M |
| Investing cash flow | $2.73M | $3.67M | $2.77M | $4.18M | $3.65M | $2.82M | $5.20M | -$11.06M |
| Financing cash flow | $187,000 | — | — | $782,000 | — | — | — | $0 |
| Depreciation & amortization | — | — | $31,000 | $31,000 | $31,000 | $34,000 | $40,000 | $40,000 |
| Stock-based compensation | $410,000 | $397,000 | $467,000 | $637,000 | $688,000 | $1.44M | $651,000 | $1.02M |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.